Buprenorphine pharmacotherapy for the management of neonatal abstinence syndrome in methadone‐exposed neonates
Paediatric and Neonatal Pain · 2019
DOI: 10.1002/pne2.12008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Paediatric and Neonatal Pain, 2019. Verfasst von Afshin A Taleghani und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Cincinnati Medical Center Cincinnati Ohio. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We aimed to compare the outcomes of pharmacotherapy with either buprenorphine or methadone in infants treated for neonatal abstinence syndrome (NAS) secondary to intrauterine exposure to methadone. This is a multi‐center, retrospective cohort study to assess length of treatment (LOT), hospital length of stay (LOS), and cumulative opioid exposure between infants treated with either methadone or buprenorphine for NAS secondary to in utero exposure to methadone. Infants delivered at a gestational age ≥35 weeks and a maternal history of opioid‐use disorder and/or urine drug screen positive for methadone, and postnatal pharmacotherapy for NAS with either buprenorphine or methadone as first‐line opioid replacement therapy, were eligible. Median LOT, LOS, and cumulative opioid exposure were compared between buprenorphine‐ and methadone‐treated infants. A total of 156 infants (48 treated with buprenorphine and 108 with methadone) were identified. The median LOT and LOS for buprenorphine‐treated infants was 8 and 13 days compared with 15 and 20 days for methadone‐treated infants, respectively, P < .001 for both outcomes. Median cumulative opioid dose in morphine equivalents was 0.6 mg/kg for buprenorphine‐treated infants vs 1.05 mg/kg for methadone‐treated infants, P < .001. No adverse effects were noted among either group. Of infants treated with buprenorphine, 34 (71%) required the addition of adjunctive pharmacotherapy during the NICU stay, compared with 31 (32%) in the methadone‐treated group, P = .0008. However, significantly fewer infants treated with buprenorphine required continuation of therapy beyond discharge as compared with those treated with methadone. The difference is most likely a reflection of the protocols used by the sites. In infants that required pharmacotherapy for NAS secondary to intrauterine exposure to methadone, treatment with buprenorphine, compared with methadone therapy, was associated with better outcomes. If confirmed with prospective data, buprenorphine could be considered first‐line therapy for the two medication‐assisted treatment regimens recommended by the American College of Obstetricians and Gynecologists.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Cincinnati Medical Center Cincinnati Ohio.
- James L. Winkle College of Pharmacy University of Cincinnati Cincinnati Ohio.
- Department of Pediatrics University of Cincinnati Cincinnati Ohio.
- Division of Neonatology and Pulmonary Biology Cincinnati Children's Hospital Medical Center Cincinnati Ohio.
- St. Elizabeth Medical Center Edgewood Kentucky.
- Mercy Hospital Anderson Cincinnati Ohio.
ORCID-Profile: Afshin A Taleghani
Zitieren
APA
Taleghani, A. A., Isemann, B. T., Rice, W. R., Ward, L. P., Wedig, K. E., & Akinbi, H. T. (2019). Buprenorphine pharmacotherapy for the management of neonatal abstinence syndrome in methadone‐exposed neonates. Paediatric and Neonatal Pain. https://doi.org/10.1002/pne2.12008
Vancouver
Taleghani AA, Isemann BT, Rice WR, Ward LP, Wedig KE, Akinbi HT. Buprenorphine pharmacotherapy for the management of neonatal abstinence syndrome in methadone‐exposed neonates. Paediatric and Neonatal Pain. 2019. doi:10.1002/pne2.12008
BibTeX
@article{Taleghani2019,
author = {Taleghani, Afshin A and Isemann, Barbara T and Rice, Ward R and Ward, Laura P and Wedig, Kathy E and Akinbi, Henry T},
title = {Buprenorphine pharmacotherapy for the management of neonatal abstinence syndrome in methadone‐exposed neonates},
journal = {Paediatric and Neonatal Pain},
year = {2019},
doi = {10.1002/pne2.12008}
}
EUVIMED